Phathom Pharmaceuticals(US:PHAT) Newsfilter·2025-04-01 12:00Core Viewpoint - Phathom Pharmaceuticals has appointed Steven Basta as the new President and CEO, succeeding Terrie Curran, to lead the company during a critical growth phase focused on expanding the commercial potential of its gastrointestinal treatments, particularly VOQUEZNA [1][2]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal diseases, with a focus on the potassium-competitive acid blocker, vonoprazan, marketed as VOQUEZNA [5]. Leadership Transition - Steven Basta brings over 25 years of experience in the biopharmaceutical and medical device industries, having previously served as CEO at various companies, including SaNOtize and Mahana Therapeutics [3][4]. - Terrie Curran, the former CEO, expressed pride in the company's achievements over the past five years and confidence in its future growth potential [2]. Strategic Focus - The Board of Directors aims to accelerate commercial growth and enhance shareholder value under Basta's leadership, leveraging his extensive experience in product development and commercial strategy [2][3]. - Basta emphasized the need for innovative treatment options in the gastrointestinal market and Phathom's unique position to capture significant opportunities [2].